Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Selinexor
Karyopharm Therapeutics
Glioblastoma
1 trial -
Selinexor
Karyopharm Therapeutics
Glioblastoma Multiforme
1 trial -
Selinexor
Karyopharm Therapeutics
Myelodysplastic Syndrome
1 trial -
Selinexor (KPT-330)
Karyopharm Therapeutics
Squamous Cell Carcinoma
1 trial -
Selinexor 100 mg
Karyopharm Therapeutics
Non-Small Cell Lung Carcinoma (NSCLC)
1 trial -
Selinexor 20 MG Oral Tablet
Karyopharm Therapeutics
Multiple Myeloma
1 trial -
Selinexor 60 MG
Karyopharm Therapeutics
Multiple Myeloma
1 trial -
Selinexor 60 mg
Karyopharm Therapeutics
Myelofibrosis
1 trial -
selinexor
Karyopharm Therapeutics
Richter's Transformation
1 trial -
selinexor (KPT-330)
Karyopharm Therapeutics
Myelodysplastic Syndromes
1 trial -
Eltanexor
Karyopharm Therapeutics
Relapsed Myelodysplastic Syndrome
1 trial -
KCP-330
Karyopharm Therapeutics
Sarcoma
1 trial -
KPT-330
Karyopharm Therapeutics
Hematological Malignancies
1 trial -
KPT-330
Karyopharm Therapeutics
Solid Tumors
1 trial -
KPT-330
Karyopharm Therapeutics
Diffuse Large B-Cell Lymphoma
1 trial -
KPT-330
Karyopharm Therapeutics
Relapsed Acute Lymphoblastic Leukemia (ALL)
1 trial -
KPT-9274
Karyopharm Therapeutics
Solid Tumors
1 trial -
KPT-9274
Karyopharm Therapeutics
Acute Myeloid Leukemia
1 trial -
Selinexor
Karyopharm Therapeutics
Liposarcoma
1 trial -
Selinexor
Karyopharm Therapeutics
Colorectal Neoplasm
1 trial -
Selinexor
Karyopharm Therapeutics
Amyloid
1 trial -
Selinexor
Karyopharm Therapeutics
Prolymphocytic Leukemia
1 trial -
Selinexor
Karyopharm Therapeutics
Refractory Multiple Myeloma
1 trial -
Selinexor
Karyopharm Therapeutics
Soft Tissue Sarcoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources